Prescribing naloxone to actively injecting heroin users: A program to reduce heroin overdose deaths

Journal of Addictive Diseases

Volumn 25, Issue 3, 2006, Pages 89-96

  Maxwell, Sarz ^a   Bigg, Dan ^a   Stanczykiewicz, Karen ^a   Carlberg Racich, Suzanne ^a  

^a Chicago Recovery Alliance   (United States)

Author keywords

Injection drug user; Opiate addiction; Opiate overdose

Indexed keywords

DIAMORPHINE; NALOXONE;

ARTICLE; CONTROLLED STUDY; DRUG FORMULARY; DRUG OVERDOSE; DRUG USE; HEALTH EDUCATION; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; INJECTION; MORTALITY; PATIENT EDUCATION; PRESCRIPTION;

CATCHMENT AREA (HEALTH); DRUG PRESCRIPTIONS; DRUG THERAPY; HEROIN DEPENDENCE; HUMANS; ILLINOIS; LIABILITY, LEGAL; NALOXONE; NARCOTIC ANTAGONISTS; OVERDOSE; PRESCRIPTIONS, DRUG; PREVALENCE; PROGRAM DEVELOPMENT; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33748455452     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v25n03_11     Document Type: Article

References (23)

1. Davidson JP, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997-2000: a case of targeted intervention. J Urban Health. Jun 2003; 80(2):261-273.
2. Degenhardt L, Hall W, Adelstein BA. Ambu-lance calls to suspected overdoses: New South Wales patterns July 1998 to June 1999. Aust NZ J Public Health. Oct 2001; 25(5):447-450.
3. Hall W, Darke S. Trends in opiate overdose deaths in Australia 1979-1995. Drug Alcohol Depend. Sep 1, 1998; 52(1):71-77.
4. Hall WD, Degenhardt LJ, Lynskey MT. Opioid overdose mortality in Australia, 1964-1997: birth-co- hort trends. Med J Aust. 1999 17(1):34-37.
5. Oliver P, Keen J. Concomitant drugs of misuse and drug using behaviours associated with fatal opiate-related poisonings in Sheffield, UK, 1997-2000. Addiction. Feb, 2003; 98(2):191-197.
6. Preti A, Miotto P, DeCoppi M. Deaths by unin-tentional illicit drug overdose in Italy, 1984-2000. Drug Alcohol Depend. 2002; 66(3):275-282.
7. Patterns and Trends of Drug Abuse in Chicago. Illinois Drug Threat Assessment Update. National Drug Intelligence Center Product No. 2002-S0382IL-001, Jan-uary 2001.
8. Seal KH, Downing M, Kral AH, Singleton- Banks S, Hammond JP, Lorvick J, Ciccarone D, Edlin BR. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health. Jun, 2003; 80(2): 291-301.
9. Hoffman RS, Goldfrank LR. The poisoned par-ticipant with altered consciousness. Controversies in the useof a ‘coma cocktail.’ JAMA. 1995; 274(7):562-569.
10. Physician’s Desk Reference, 57th Edition, 2003. American Diabetes Association. Standards of medical care of participants with diabetes mellitus. Diabetes Care 24(suppl 1):S33-S43 [32 references] 1988, Republished Jan 2001.
11. Joint Task Force on Practice Parameters, Ameri-can Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis. J Allergy Clin Immunol. 1998; 101(6pt2) S465-S528.
12. Darke S, Hall W. The distribution of naloxone to heroin users. Addiction. 1997; 92(9):1195-1199.
13. Lenton SR, Hargreaves KM. Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose? Med J Aust. 2000; 173(5):260-263.
14. Bigg D. Data on take home naloxone are unclear but not condemnatory. BMJ. 2002; 324(7338):678.
15. Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Flahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003; 80(2):288-290.
16. Burris S, Norland J, Edlin BR. Legal aspects of providing naloxone to heroin users in the US. Int J. Drug Policy. 2001; 12:237-248.
17. Christenson J, Etherington J, Grafstein E, Innes G, Pennington S, Wanger K, Fernandes C, Spinelli JJ, Gao M. Early discharge of patients with presumed opioid overdose: development of a clinical prediction rule. Acad Emerg Med. 2001; 8(4):403-404.
18. Clarke, S, Dargan P. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Discharge of patients who have taken an overdose of opioids. Emerg Med J. 2002; 19(3): 250-251.
19. Vilke GM, Buchanan J, Dunford JV, Chan TC. Are heroin overdose deaths related to participant release after prehospital treatment with naloxone? Prehosp Emerg Care. 1999; 3(3):183-186.
20. Vilke GM, Sloane C, Smith AM, Chan TC. As-sessment for deaths in out-of-hospital heroin overdose participants treated with naloxone who refuse transport. Acad Emerg Med. 2003; 10(8):893-896.
21. Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, Gossop M. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow-up study. BMJ. 2003; 326(7396):959-960.
22. Ritter AJ. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust NZ J Psychiatry. 2002; 36(2):224-251.
23. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998; 52(3):257-260.